The most common side effects include gastrointestinal related symptoms such as nausea, indigestion, abdominal pain, diarrhea, constipation, and vomiting
Additional indications vary between drugs, with semaglutide approved for use in 12 years and above for weight management, while tirzepatide is approved for use in 10-year-olds and above for T2DM Both medications share similar gastrointestinal side effects, which leads many patients to discontinue use, as well as boxed warnings regarding the risk of thyroid tumors
Move over protein
Even if you were on the maximum 2.4 mg of semaglutide, you start tirzepatide at its lowest dose
In: Impulscytophotometrie, 59-65, 1975
Here's how the global rollout typically works for new GLP-1 medications: EMA (European Medicines Agency) Review timeline: EMA often reviews in parallel with FDA but usually approves 6-18 months after FDA